|June 2015||Media article||“Chinese Herbal Medicine May Have Delayed Benefit in Stroke”
A press article detailing the exciting new clinical results of CHIMES-E study showing the persisting benefits of NeuroAiD in post-stroke recovery was published online on Medscape.com
|June 2015||Press Release||“NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset”
Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 1719, as part of the Scientific Program during the Clinical Trial session.
|August 2014||Presentation||27th August 2014 – Moleac’s CEO, David Picard, presented on “E-Commerce: Going beyond the traditional visibility of Pharma Products” at the Pharmaceutical Congress Asia that was held from 26th to 29th August 2014 at the Park Royal Hotel in Singapore. His presentation included an introduction to NeuroAiD™ as well as Moleac’s Corporate Social Responsibility (CSR) activities and commitment to patient care via the Stroke Recovery Coach.||EN|
|July 2014||Press Article||“TCM trial for stroke survivors – Professor Christopher Chen is interviewed about the NeuroAiD™II in Vascular Cognitive Impairment Study (NEURITES) in The Straits Times.”||EN|
|July 2014||Press Article||“NUS studies the efficacy of traditional Chinese Medicine in treating stroke’s after-effects – featured in Lian He Zao Pao”||CH|
|April 2014||Press Release||Moleac is happy to announce the appointment of Elmar Schnee as non-executive Chairman of the company||EN|
|Jan – Feb 2014||Press Article||“Demonstrated efficiency of NeuroAiD™”
A press article detailing the exciting latest clinical data on vascular events reduction after a stroke has been published in the magazine “Actifs”
|EN / FR|
|Oct 2013||Press Release||NeuroAiD™, a treatment for post-stroke recovery, reduced early cardiovascular events and deaths by half after stroke
Singapore, 21st October 2013 – Early vascular events are an important cause of morbidity and mortality in the first three months after a stroke. The CHIMES Study is a placebo-controlled trial of NeuroAiD™, having included 1099 patients with ischemic stroke and receiving appropriate secondary prevention treatments. The frequency of early cardiovascular events and deaths during the 3-month follow-up was significantly halved in the NeuroAiD™, group (p=0.025) without an increase in bleeding rate and non-vascular deaths.
|Jul 2013||Radio Interview||Presenter of ‘Body & Soul’ program on 938LIVE Daniel Martin interviews Prof Christopher Chen on Stroke in Singapore and the CHIMES Study.
938LIVE is a poplar news-focused radio station. ‘Body & Soul’, since it first aired in 2007, has been Singapore’s only dedicated daily health radio talk-show.
|Jun 2013||Press Release||Stroke Treatment based on Traditional Chinese Medicine increases chances of recovery
|Mar 2013||Press Release||NeuroAiD™, a stroke treatment based on traditional Chinese medicine, more than doubles the chances of achieving independence after stroke
Singapore, March 19 2013: Authors of a medical paper published in this month’s Cerebrovascular Diseases journal found that NeuroAiD™ significantly improves patients’ independence after suffering a stroke compared to other control groups. During the studies stroke patients taking NeuroAiD™ were twice as likely able to take care of themselves and speak freely. The study also showed that NeuroAiD™ improved patients’ chances of performing daily activities after stroke.
|Jan 2013||Media Coverage||NurAiD™II is featured on France 24 with an interview with neurologist and prescriber Dr Charles Siow, CEO David Picard and lead investigator of the CHIMES trial Prof Christopher Chen about bringing Chinese medicine into the Western standards to fill the gap of improving recovery after stroke.||EN||YouTube|
|Jul 2011||Press Release||Moleac Announces the Beneficial Effect of NeuroAiD (TM) (MLC 901) in Protecting the Brain Against Global Ischemia
“Neuropharmacology” published a paper establishing NeuroAiD’s reparativeeffects on global cerebral ischemia.
|Feb 2011||Press Release||Prof. Michel Lazdunski receives Gold Medal from the Jung Foundation for his work on ion channels.
We are happy to announce that Prof. Michel Lazdunski, vice president research of Moleac, has been awarded one of the most prestigious international awards – the 2011 Gold Medal of the Jung Foundation for Science and Research, for his work on ion channels.
|Mar 2010||Press Release||Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award
Moleac Pte Ltd has been granted the Emerging Company of the Year 2010 Award, by Biospectrum, the leading integrated media platform for the Life Science Industry in Asia Pacific.
|Feb 2010||Press Release||Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD
The January issue of “Neuropharmacology”, publishes the article entitled “Neuroprotective and Neuroproliferative Activities of NeuroAiD”, reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.
|Sep 2009||The Business Times||Faster, cheaper way to developing drugs (next paragraph) Moleac’s hybrid approach has been used to successfully develop and market its stroke recovery drug in 3 years, for less than US$10m||EN|
|Apr 2009||Press Release||Moleac named Singapore Entrepreneurial Company of the year at the Frost & Sullivan Excellence in Healthcare Award
An important confirmation of Moleacs outstanding performance in 2008.
|Apr 2009||The Business Time||Moleac is rewarded for its stroke treatment drug NeuroAiD||EN|
|Apr 2009||Medical Tribune||TCM agent shows promise in post-stroke recovery, says study
An article on clinical trials performed in China shows promising results and paves the first steps towards making NeuroAiD an evidence-based medicine.
|Feb 2009||Press Release||Moleac Prof. Michel Lazdunski appointed as Vice-President Research of Moleac Pte. Ltd.
A world-renown scientific leader is now in charge of the study on NeuroAiD mechanism of action.
|Feb 2009||Medical Tribune||Evidence-based TCM makes headway NeuroAiD™ is one of the first TCM medications to be put under the microscope of rigidly-controlled clinical trials CHIMES continues to make noises in Singapore and giving hope to stroke patients.||EN|
|Dec 2008||BioSpectrum||Ancient medicines, source of Pharma innovation – Moleac aims to bring the science behind traditional medicines to the next level and establishes their quality and safety through accepted modern evaluation practices.||EN|
|Oct 2008||Le Quotidien du Medecin (original in French)||Un composé issu de la médecine chinoise au banc d’essai. L’un des magazines les plus renommés parmi les médecins français a accordé une attention particulière à NeuroAiD™.
A mixture derived from Chinese medicine on trial. One of the most prestigious magazine for doctors in France has paid special attention to NeuroAid&trade.
|May 2008||The Edge||Bridging the gap between East and West – Moleac unique business model differs itself from other biotech companies in valuations or the way in which the investors consider.||EN|
|Apr 2008||The Business Times Weekend News||China Stroke Drug Holds Promise.||EN|
|Apr 2008||The Business Times Weekend News||Three-Minute Digest: US$3.5M more for Moleac for stroke drug trials.||EN|
|Sep 2007||The Business Times Weekend||Largest TCM trial outside China.||EN|
|Sep 2007||Singapore Straits Times||TCM drug for stroke to undergo clinical trials.||EN|
|Sep 2007||Channel News Asia||Channel News Asia 880 stroke patients in Singapore to undergo TCM clinical trial.||EN||mp4|
|Sep 2007||The Business Times||The Business Times Moleac plans to test traditional Chinese stroke drug.||EN|
|Sep 2007||Moleac announces CHIMES||Largest ever clinical trial on stroke recovery medication to be initiated in Singapore and Philippines.||EN|
|Sep 2007||Reuters||Singapore firm tests traditional Chinese stroke drug.||EN|
|May 2007||Medical News Today||Going West with Eastern Medicine.||EN|
|Apr 2007||AsiaOne||Chinese medicine to help stroke victims||EN|
|Apr 2007||Straits Times||Rise of Traditional Chinese Medicine||EN|
|Dec 2006||Reuters||Moleac Turns TCM into Stroke Treatment||EN|
|Dec 2006||Focus Autumn||Moleac: Therapeutics from East to West.||EN|
|Dec 2006||Today’s Manager||Uncovering New Drugs from Traditional Cures.||EN|
|Oct 2006||The Business Times||New TCM drug offers hope for stroke patients.||EN|
|Sep 2006||Press release||Moleac and China healthcare tie up to offer a more comprehensive rehabilitation treatment for stroke patients.||EN|
|Aug 2006||The Edge||Traditional Therapy||EN|
|Aug 2006||Talking Science (children magazine)||East meets West||EN|
|Aug 2006||EZHealth||NeuroAiD for stroke patients||EN|
|Jun 2006||Press release||NeuroAiD offers new hope to patients||EN|
|Apr 2006||Singapore Business Visitor||The Next Wave||EN|
|Jan 2006||Asia Pacific Biotech Journal||Moleac: Flowing Therapeutics from the East to the West and Expertise from the West to the East.||EN|